

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: A61K 31/135, 47/48, 9/127 A61K 9/107	A1	(11) International Publication Number: WO 93/11757 (43) International Publication Date: 24 June 1993 (24.06.93)
(21) International Application Number: PCT/FI92/00339 (22) International Filing Date: 10 December 1992 (10.12.92) (30) Priority data: 9126209.7 10 December 1991 (10.12.91) GB (71) Applicant (for all designated States except US): ORION-YH-TYMÄ OY [FI/FI]; Orionintie 1, SF-02200 Espoo (FI). (72) Inventors; and (75) Inventors/Applicants (for US only): JALONEN, Harry, Gösta [FI/FI]; Hurtinkatu 4a, SF-20600 Turku (FI). HEIKKILÄ, Terttu, Marita [FI/FI]; Vuorikatu 7aB33, SF-20700 Turku (FI). JALONEN, Hannu, Uolevi [FI/FI]; Rakuunatie 60A6, SF-20720 Turku (FI). KANGAS, Lauri, Veikko, Matti [FI/FI]; Pasantie 3B, SF-21280 Raisio (FI). LAMMINTAUSTA, Risto, Arvo, Sakari [FI/FI]; Meltoistentie, SF-20900 Turku (FI). KURKELA, Kauko, Oiva, Antero [FI/FI]; Pampinkuja 1C, SF-20900 Turku (FI).	(74) Agent: ORION CORPORATION; c/o Orion-Farmos Pharmaceuticals, Patent Department, P.O. Box 65, SF-02101 Espoo (FI). (81) Designated States: AU, BG, CA, CS, FI, HU, JP, KR, NO, NZ, PL, PT, RO, RU, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: DRUG FORMULATIONS FOR PARENTERAL USE (57) Abstract <p>This invention relates to parenteral preparations of antiestrogens such as toremifene, desmethyl toremifene, tamoxifen or desmethyltamoxifen. The preparations can be emulsions, liposomes or aqueous solutions of cyclodextrin-drug complexes. Particularly the invention relates to a parenteral drug formulation comprising a complex having a 2-hydroxypropyl cyclodextrin component and including an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof, said complex being present either in an aqueous solution or emulsion or loaded into a liposome.</p>		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

Drug formulations for parenteral use

This invention relates to drug formulations of antiestrogens, particularly antiestrogens comprising a triphenylbutene moiety, for use in parenteral administration.

Toremifene, desmethyl toremifene, desmethyl tamoxifen and tamoxifen are all examples of substituted triphenylbutenes useful in cancer therapy. Reference is made to US 4696949, US 4990538 and US 4356516. They can all be described with the formula



in which R_1 is CH_3 or H and R_2 is H or Cl.

The compounds mentioned above have the following values of R_1 and R_2 ;

	R_1	R_2
toremifene	CH_3	Cl
desmethyl toremifene	H	Cl
tamoxifen	CH_3	H
desmethyl tamoxifen	H	H

A common feature of these antiestrogens is their poor solubility in water. Thus, parenteral administration of these drugs cannot be accomplished simply by an aqueous solution of the active ingredients.

There is a clear need for parenteral formulations of the anticancer antiestrogens. Injectable high-concentration toremifene formulations will have important clinical benefit

- 1) in the attempts to reach high concentrations in tissue. This is necessary especially when combinations of toremifene with cytotoxic drugs are given to a

patient. As shown by DeGregorio et al (J Clinical Oncology, vol 7, No 9, 1989: 1359 - 1364.) high plasma concentrations are more effective in reversing multidrug resistance than low concentrations. An injectable formulation enables high peak concentrations in blood and tissues without exposing the patient to long-term treatment;

- 2) when given locally into a tumor. This enables a high and efficacious concentration in the tumor to be achieved;
- 3) when used topically in a benign estrogen-dependent lesion like cystic mastalgia, where toremifene can be injected directly into a painful cyst;
- 4) when spreading toremifene topically onto palpable and subcutaneous breast cancer metastases;
- 5) when an intravesical installation is given for the therapy of superficial bladder cancer. In this indication toremifene may well be used together with other anticancer drugs to enhance their efficacy;
- 6) when an intraperitoneal solution is given for the treatment of certain types of ovarian cancer;
- 7) when other topical, estrogen-dependent lesions are treated with an antiestrogen.

The parenteral drug formulations according to this invention include emulsions, aqueous solutions of cyclodextrin - drug complexes and liposomes.

Dissolution properties of drugs can be significantly improved by complexation of the drug substance with cyclodextrins. Cyclodextrins (including α , β and γ cyclodextrins and their derivatives) are all cyclic oligomers of glucose. The

cyclodextrins can form inclusion complexes with drugs in that the drug molecule is included in the lipophile-seeking cavities of the cyclodextrin molecule. Therefore the cyclodextrins effectively solubilize lipophilic drugs into aqueous media. The use of cyclodextrins in the pharmaceutical field has been described e.g. in Drug Development and Industrial Pharmacy, 17(11), 1503-1549, 1991.

With respect to the antiestrogens mentioned above, however, no parenteral drug formulations based on complexation of the active drug substance with 2-hydroxypropyl cyclodextrins are known in the art. One object of this invention is a parenteral formulation based on a 2-hydroxypropyl cyclodextrin, preferably 2-hydroxypropyl β -cyclodextrin or 2-hydroxypropyl- γ -cyclodextrin, complex including an active drug substance selected from the group consisting of toremifene, desmethyltoremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof, said complex being present in an aqueous solution.

Emulsions of the antiestrogens mentioned above can be made by dispersing the drug or a cyclodextrin complex of said drug into a pharmaceutically acceptable emulsifier, and optionally adding a stabilizing agent.

Parenteral administration of the drugs mentioned above may also be accomplished by aqueous solutions of liposomes containing said drug or a salt thereof. Liposomes are spherical particles in an aqueous medium, formed by a lipid bilayer enclosing an aqueous compartment. The lipid surface may be either unilamellar or multilamellar. The liposomes may be loaded with either hydrophobic or hydrophilic drug substances.

Another object of the invention is a parenteral formulation based on the drug substance as such loaded into liposomes. Such liposomes can be made by dissolving the drug or drug-cyclodextrin complex together with a phospholipid component, preferably DMPC (dimyristoylphosphatidylglycerol) and/or POPC

(= 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphorylcholine), in a chloroform - methanol mixture, evaporating the solvent, dissolving the residue into water followed by homogenization. According to this invention liposomes can be made directly by dissolving the drug or the drug-cyclodextrin complex and phospholipid component directly in water without foregoing dissolving into chloroform - methanol mixture.

Another object of this invention is a parenteral formulation based on a 2-hydroxypropyl cyclodextrin, preferably 2-hydroxypropyl β -cyclodextrin or 2-hydroxypropyl Γ -cyclodextrin, complex including an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof, said complex being loaded into a liposome.

Preparation of the antiestrogen-2-hydroxypropyl cyclodextrin complexes:

A weighed amount of 2-hydroxypropyl cyclodextrin was dissolved into distilled water by shaking with a shaker. The so formed clear solution was equilibrated with a large excess of antiestrogen at the boiling point. After removing the almost clear solution the excess of antiestrogen started to precipitate. The solution was kept overnight at room temperature and the excess of precipitated antiestrogen was removed by centrifugation.

Measurement by HPLC of the solubility of the anti-estrogen in an aqueous solution of 2-hydroxypropyl cyclodextrin.

The fully automated HPLC apparatus (Hewlett-Packard, USA) consisted of a pump 1090, an autosampler and autoinjector (79847A) with an injection volume of 10 μ l and a fixed wavelength UV detector, 280 nm (79881A). The chromatograms and peak areas were recorded with an integrator 3393. The separations were carried out at room temperature on a 35 *

4.6 mm stainless steel column (packed with 3- μ m spherical octadecylsilanebonded silica particles; HS-3 C-18, (Perkin-Elmer, USA))

The mobile phase consisted of a mixture of acetonitrile : 0.05 M aqueous phosphate buffer containing 0.004 M of dimethyloctyl amine with a pH of 7.4. The flow rate was 0.8 ml/min.

Preparation of the liposomes:

1) Liposomes based on cyclodextrin - drug complexes and prepared by dissolving the components in an organic solution

2-hydroxypropyl- β -cyclodextrin (12 mg), POPC (32 mg), cholesterol (4 mg), DMPG (dimyristoylphosphatidylglycerol) (8 mg) and toremifene citrate (2 mg) were dissolved in chloroform - methanol (2:1) and evaporated. The residue was dissolved in water and homogenized by sonication (Labsonic U, 50 W). The stability of the solution was good; no turbidity was observed after one month in room temperature.

2) Liposomes based on cyclodextrin - drug complexes and prepared by dissolving and homogenizing components directly in water

2-hydroxypropyl- β -cyclodextrin (24 mg), DMPG (dimyristoylphosphatidylglycerol) (16 mg) and toremifene citrate (2 mg) were simultaneously dissolved in 2 ml water and homogenized by sonication (Labsonic U, 50 W). The final solution was as clear as the solution above. The mean particle diameter of these two solutions were about 100 nm (Nicomp 370/HPL high power laser option). The solution was stable after one week storage at room temperature.

3) Liposomes which were not based on cyclodextrin complexes

Preparation of these solutions was attempted by dissolving the components directly into water. The only composition which gave a clear or slightly opalescent solution was DMPG (16 or 32 mg), toremifene citrate (2 mg) dissolved and homogenized by sonication (50 W) in 2 ml water. The stability of the solutions were not however good enough; solutions became a bit turbid in one month storage at room temperature, e.g., the composition toremifene citrate (2 mg), DMPG (32 mg) and cholesterol (4 mg) was not able to dissolve and homogenized in 2 ml water.

These results indicate that stable liposomes cannot be achieved in the absence of a cyclodextrin component especially if the drug and phospholipid are mixed directly into water.

However, cyclodextrin-free liposomes can be made by mixing the ingredients first in chloroform/ethanol (2:1) as described above for the cyclodextrin-containing liposomes.

Solubility results

Formulation

Toremifene solubility

mg of toremifene
ml of cyclodextrin-water soln.

500 mg β -HPC/ml of aqueous soln.	87.7
250 "	53.0
125 "	21.7
63 "	14.1
25 "	7.4
0 "	0.3

β -HPC = 2-hydroxypropyl- β -cyclodextrin

500 mg Γ -HPC/ml of aqueous soln.	125.4
250 "	61.1
125 "	36.3

Γ -HPC = 2-hydroxypropyl- Γ -cyclodextrin

Tamoxifen solubility

mg of tamoxifen
ml of cyclodextrin-water soln.

500 mg β -HPC/ml of aqueous soln.	67.4
250 "	43.3
125 "	23.5
63 "	13.3
25 "	6.1
0 "	< 1.0

Desmethyl toremifene solubility

mg of desmethyl toremifene
ml of cyclodextrin-water soln.

125 mg β -HPC/ml of aqueous soln.	21.0
---	------

The pharmacokinetics of the toremifene formulations described above, when give intravenously, resemble closely those of perorally given toremifene. However, during the first minutes and 1-2 hours the concentrations of the intravenously given drug are high, while the drug, when given per os, has not yet been absorbed completely from the gastrointestinal tract.

Preparation of emulsions:

Emulsions prepared by dissolving the drug in a commercial fat emulsion.

The commercial fat emulsion used was Emulsan® 20 % (manufacturer Leiras-Kabi Infusion Ltd., Finland). Different amounts of toremifene citrate were dissolved in Emulsan solution and homogenized by sonication (Labsonic U, 50 W). The toremifene concentrations were 10 mg/ml, 14 mg/ml and 20 mg/ml. After the homogenization the samples were filtered through the 0.2 μ m, 0.45 μ m and 1.2 μ m filters.

The concentration of toremifene was determined from the filtrate with a spectrophotometric method using the wave length of 278 nm. The samples were dissolved in methanol and diluted in the concentration of 0.02 mg/ml.

The results are presented in the following table:

Concentration before filtration [mg/ml]	Size of the filter [μ m]	Concentration after filtration [mg/ml]
10	0.2	4.4
	0.45	4.0
	1.2	4.4
14	0.45	4.3
	1.2	3.7
20	0.45	3.6
	1.2	3.6

The results show that the solubility of toremifene can be increased considerably by encapsulating the toremifene in an emulsion droplet.

Claims .

1. A parenteral drug preparation in the form of an emulsion or liposome of an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof.
2. A preparation according to claim 1 where the drug is toremifene or its non-toxic, pharmaceutically acceptable salt.
3. A parenteral drug formulation comprising an aqueous solution of a complex which comprises a 2-hydroxypropyl cyclodextrin component and an active drug component in which the active drug is selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyl tamoxifen or a pharmaceutically acceptable non-toxic salt thereof.
4. A formulation according to claim 3 where the 2-hydroxypropyl cyclodextrin component is 2-hydroxypropyl- β -cyclodextrin.
5. A formulation according to claim 3 where the 2-hydroxypropyl cyclodextrin component is 2-hydroxypropyl- γ -cyclodextrin.
6. A formulation according to claim 3 to 5 where the drug is toremifene or its non-toxic pharmaceutically acceptable salt.
7. A parental drug formulation comprising an emulsion or liposome comprising a complex which comprises a 2-hydroxypropyl cyclodextrin component and an active

drug component in which the active drug is selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof.

8. A formulation according to claim 7 where the 2-hydroxypropyl cyclodextrin component is 2-hydroxypropyl- β -cyclodextrin.
9. A formulation according to claim 7 or 8 where the drug is toremifene or its non-toxic pharmaceutically acceptable salt.
10. A method of treatment of an estrogen-dependent tumor in a mammal comprising administering parenterally to said mammal an amount of a formulation as claimed in claim 1 sufficient to produce the desired effect.
11. A method of treatment of an estrogen-dependent tumor in a mammal comprising administering parenterally to said mammal an amount of a formulation as claimed in claim 3 sufficient to produce the desired effect.
12. A method of treatment of an estrogen-dependent tumor in a mammal comprising administering parenterally to said mammal an amount of a formulation as claimed in claim 6 sufficient to produce the desired effect.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/FI 92/00339

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61K31/135; A61K47/48; A61K9/127; A61K9/107		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification Systems:	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claims No. ¹³
P, X	CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; abstract no. 158718p. T. LOFTSSON ET AL. 'solubilization and stabilization of drugs through cyclodextrin complexation' page 442 ;column 1 ; & ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217	1-6, 10-12 1-6, 10-12
X	---	-/--
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
12 MARCH 1993		30.03.93
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		BENZ K.F.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claims No.
X	JOURNAL OF CHROMATOGRAPHY, BIOMEDICAL APPLICATIONS vol. 414, no. 1, 20 February 1987, AMSTERDAM (NL) pages 192 - 196 R.D. ARMSTRONG ET AL. 'separation of tamoxifen geometric isomers and metabolites by bonded-phase beta-cyclodextrin chromatography' see the whole document	1-2, 10-12
A	WO,A,9 117 749 (BAYLOR COLLEGE OF MEDICINE) 28 November 1991 see page 1, line 5 - line 10 see page 39, line 25 - page 41, line 3	1-6, 10-12
X	FEBS LETTERS vol. 274, no. 1,2, November 1990, AMSTERDAM (NL) pages 107 - 110 H. WISEMAN ET AL. 'mechanism of inhibition of lipid peroxidation by tamoxifen and 4-hydroxytamoxifen introduced into liposomes' see the whole document	1,2 7-9
Y	DE,A,3 331 459 (FINK ET AL.) 1 March 1984 see claim 1	1,2
Y	EP,A,0 355 604 (LEDERLE (JAPAN) ET AL.) 28 February 1990 see claims 1-20	1,2
Y	FR,A,2 502 951 (SANDOZ SA) 8 October 1982 see page 24; claim 2 see page 28, line 2 - line 3	1,2
Y	WO,A,9 006 106 (PATRINOVE) 14 June 1990 see page 3, line 24 - line 36	7-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 92/00339

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
ALTHOUGH CLAIMS 10-12 ARE DIRECTED TO A METHOD OF TREATMENT OF THE HUMAN/
ANIMAL BODY THE SEARCH HAS BEEN CARRIED OUT AND BASED ON THE ALLEGED EFFECT
S OF THE COMPOSITION.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

FI 9200339
SA 68161

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 12/03/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9117749	28-11-91	AU-A- 7963691 EP-A- 0528975	10-12-91 03-03-93
DE-A-3331459	01-03-84	None	
EP-A-0355604	28-02-90	JP-A- 2138211 US-A- 5004756 US-A- 5182267	28-05-90 02-04-91 26-01-93
FR-A-2502951	08-10-82	CH-A- 653256 CH-A- 647149 AU-A- 6508486 AU-B- 564570 AU-A- 8233482 BE-A- 892709 CA-A- 1192496 DE-A- 3212053 FR-A- 2572933 GB-A, B 2098865 GB-A, B 2148711 JP-A- 57181007 NL-A- 8201413 SE-A- 8202172	31-12-85 15-01-85 12-03-87 20-08-87 14-10-82 30-09-82 27-08-85 21-10-82 16-05-86 01-12-82 05-06-85 08-11-82 01-11-82 07-10-82
WO-A-9006105	14-06-90	FR-A- 2640137	15-06-90

EP 0 304 007

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82